nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.05.2013 | Original Article

Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel

verfasst von: Hao Wu, Min Huang, Mingjie Lu, Wei Zhu, Yongqian Shu, Peng Cao, Ping Liu

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Human miR-34c has been reported to be associated with various human malignancies; however, it remains unknown whether miR-34c is involved in chemoresistance in gastric cancer. The aim of this study was to investigate the role of miR-34c in gastric cancer.

Materials and methods

The adenosine triphosphate-based tumor chemosensitivity assay was used to measure drug sensitivity in gastric cancer samples. The expression levels of miRNA were determined by reverse transcriptase polymerase chain reaction (PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The methylation status of neighboring CpG islands of miR-34c-5p was analyzed by Bisulfite Sequencing PCR and methylation-specific PCR.

Results

Quantitative real-time polymerase chain reaction demonstrated that expression of miR-34c-5p was downregulated in paclitaxel-resistant gastric cancer samples (p < 0.01). Cells derived from gastric cancer tissues with low miR-34c-5p expression and high microtubule-associated protein tau (MAPT) protein expression tended to have increased chemoresistance to paclitaxel in vitro. Luciferase activity assay confirmed that the 3′-UTR of MAPT mRNA contains a functional miR-34c-5p binding site. Overexpression of miR-34c-5p significantly downregulated MAPT protein expression and increased the chemosensitivity of paclitaxel-resistant gastric cancer cells. Further investigation demonstrated that differential methylation of CpG islands neighboring the miR-34c promoter regulated the expression of miR-34c-5p in gastric cancer cell lines.

Conclusions

DNA methylation, dysregulation of miR-34c-5p, and MAPT expression are critical factors in the chemoresistance of gastric cancer to paclitaxel.

Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D’Amico TA et al (2010) NCCN gastric cancer panel. Gastric cancer. J Natl Compr Canc Netw 8:378–409PubMed

Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M et al (2007) Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 25:3210–3216PubMedCrossRef

Takeyoshi I, Makita F, Tanahashi Y, Iwazaki S, Ogawa T et al (2011) A phase II study of weekly paclitaxel and doxifluridine combination chemotherapy for advanced/recurrent gastric cancer. Anticancer Res 31:287–291PubMed

Ludwig AH, Kupryjañczyk J (2006) Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy? Clin Cancer Res 12:6204PubMedCrossRef

Gao J, Lu M, Yu JW, Li YY, Shen L (2011) Thymidine phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer 11:177PubMedCrossRef

Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1–19PubMedCrossRef

Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L (2005) Microtubule-associated protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 4:1149–1152PubMedCrossRef

Li QQ, Cao XX, Xu JD, Chen Q, Wang WJ et al (2009) The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel. Cell Mol Life Sci 66:504–515PubMedCrossRef

10.

Ouzier R, Rajan R, Wagner P, Hess KR, Gold DL et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315–8320CrossRef

11.

Smoter M, Bodnar L, Duchnowska R, Stec R, Grala B et al (2011) The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol 68:553–557PubMedCrossRef

12.

Drechsel DN, Hyman AA, Cobb MH, Kirschner MW (1992) Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 3:1141–1154PubMed

13.

Mimori K, Sadanaga N, Yoshikawa Y, Ishikawa K, Hashimoto M et al (2006) Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment. Br J Cancer 94:1894–1897PubMedCrossRef

14.

Zheng T, Wang J, Chen X, Liu L (2010) Role of microRNA in anticancer drug resistance. Int J Cancer 126:2–10PubMedCrossRef

15.

Hummel R, Hussey DJ, Haier J (2010) MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 46:298–311PubMedCrossRef

16.

Ma J, Dong C, Ji C (2010) MicroRNA and drug resistance. Cancer Gene Ther 17:523–531PubMedCrossRef

17.

Lee Rosalind C, Feinbaum Rhonda L, Ambros Victor (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854PubMedCrossRef

18.

Sarkar Fazlul H, Li Yiwei, Wang Zhiwei, Kong Dejuan et al (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 13:57–66PubMedCrossRef

19.

Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A et al (2011) miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 30:4386–4398PubMedCrossRef

20.

Brabletz T (2012) MiR-34 and SNAIL: another double-negative feedback loop controlling cellular plasticity/EMT governed by p53. Cell Cycle 11:215–216PubMedCrossRef

21.

Cannell IG, Bushell M (2010) Regulation of Myc by miR-34c: a mechanism to prevent genomic instability? Cell Cycle 9:2726–2730PubMedCrossRef

22.

Hagman Z, Larne O, Edsjö A, Bjartell A, Ehrnström RA et al (2010) miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 127:2768–2776PubMedCrossRef

23.

Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G et al (2012) miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 27. doi:10.1038/onc.2012.51

24.

Kurbacher CM, Cree IA (2005) Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med 110:101–120PubMed

25.

Benes V, Castoldi M (2010) Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 50:244–249PubMedCrossRef

26.

Witkos TM, Koscianska E, Krzyzosiak WJ (2011) Practical aspects of microRNA target prediction. Curr Mol Med 11:93–109PubMedCrossRef

27.

Guntur VP, Waldrep JC, Guo JJ, Selting K, Dhand R (2010) Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res 30:3557–3564PubMed

28.

Sharma N, Ramachandran S, Bowers M, Yegappan M, Brown R et al (2000) Multiple factors other than p53 influence colon cancer sensitivity to paclitaxel. Cancer Chemother Pharmacol 46:329–337PubMedCrossRef

29.

Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H (2010) The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res 12:R43PubMedCrossRef

30.

Morris PG, Fornier MN (2008) Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 14:7167–7172PubMedCrossRef

31.

Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315–8320PubMedCrossRef

32.

Yang S, Li Y, Gao J, Zhang T, Li S, Luo A, Chen H, Ding F, Wang X, Liu Z (2012) MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene doi:10.1038/onc.2012.432

33.

He C, Xiong J, Xu X, Lu W, Liu L (2009) Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 388:35–40PubMedCrossRef

34.

Agirre X, Martínez-Climent JA, Odero MD, Prósper F (2012) Epigenetic regulation of miRNA genes in acute leukemia. Leukemia 26:395–403PubMedCrossRef

35.

Hata A, Davis BN (2011) Regulation of pri-miRNA processing through Smads. Adv Exp Med Biol 700:15–27PubMedCrossRef

36.

Kim NH, Kim HS, Kim NG, Lee I, Choi HS (2011) p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal. 4:ra71PubMedCrossRef

37.

Wong MY, Yu Y, Walsh WR, Yang JL (2011) microRNA-34 family and treatment of cancers with mutant or wild-type p53. Int J Oncol 38:1189–1195PubMedCrossRef

38.

Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T et al (2011) Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 17:4965–4974PubMedCrossRef

Titel: Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel
verfasst von: Hao Wu
Min Huang
Mingjie Lu
Wei Zhu
Yongqian Shu
Peng Cao
Ping Liu
Publikationsdatum: 01.05.2013
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 5/2013
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2108-y

Springer Medizin

Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel

Abstract

Background

Materials and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer

A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

Dodging a dogma: is treating beyond progression beneficial?

Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie